How is PHGE doing recently?

BiomX (PHGE) is experiencing some challenges recently. Here's a detailed analysis:

1. **Stock Performance**: The stock has seen a significant decline of 20.02% on August 8, followed by a rebound of 15.79% on August 11. This indicates a volatile trading period with both negative and positive movements. As of August 20, the stock has decreased by 4.34%.

|code|Ticker|Name|Date|Percentage Change|market_code|
|---|---|---|---|---|---|
|PHGE|PHGE.A|BiomX|20250820|-4.343065693430664|170|

2. **FDA Hold on Clinical Trial**: The U.S. FDA has placed a clinical hold on BiomX's cystic fibrosis treatment trial, BX004, due to issues with the third-party nebulizer device used to deliver the drug. This has likely contributed to the negative sentiment surrounding the stock.
3. **Company's Response**: BiomX has submitted additional data on the nebulizer device to the FDA, hoping to resolve the hold temporarily. The company believes the FDA's concerns are specific to the device and not the drug itself, and enrollment and patient dosing outside the U.S. are continuing.
4. **Financial Position**: BiomX's second-quarter fiscal 2025 results showed a match with EPS estimates at $(0.26), reflecting cost controls but ongoing net losses and no revenue. The company's cash runway is expected to extend into early 2026, but the absence of product revenue indicates a need for future financing.

In conclusion, BiomX is facing a challenging period due to the FDA hold on its clinical trial and the associated negative impact on its stock. The company's response to the FDA's concerns and its financial position are key factors to monitor for any potential changes in the stock's trajectory.

|code|Ticker|Name|Date|Pre-Market Percentage Change|market_code|
|---|---|---|---|---|---|
|PHGE|PHGE.A|BiomX|20250820|-3.12043795620438|170|